Sino Biopharmaceutical (FRA:SMZ1) EV-to-EBIT : 8.03 (As of Apr. 30, 2024)

View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sino Biopharmaceutical's Enterprise Value is €6,101 Mil. Sino Biopharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €760 Mil. Therefore, Sino Biopharmaceutical's EV-to-EBIT for today is 8.03.

The historical rank and industry rank for Sino Biopharmaceutical's EV-to-EBIT or its related term are showing as below:

FRA:SMZ1' s EV-to-EBIT Range Over the Past 10 Years
Min: 3.28 Med: 12.54 Max: 28.11
Current: 7.91

During the past 13 years, the highest EV-to-EBIT of Sino Biopharmaceutical was 28.11. The lowest was 3.28. And the median was 12.54.

FRA:SMZ1's EV-to-EBIT is ranked better than
50.68% of 440 companies
in the Biotechnology industry
Industry Median: 8.18 vs FRA:SMZ1: 7.91

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Sino Biopharmaceutical's Enterprise Value for the quarter that ended in Dec. 2023 was €8,311 Mil. Sino Biopharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €760 Mil. Sino Biopharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 9.14%.

Sino Biopharmaceutical EV-to-EBIT Historical Data

The historical data trend for Sino Biopharmaceutical's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical EV-to-EBIT Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

20.01

23.16

4.65

13.23

10.96

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															4.65	-	13.23	-	-

Competitive Comparison of Sino Biopharmaceutical's EV-to-EBIT

For the Biotechnology subindustry, Sino Biopharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sino Biopharmaceutical's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's EV-to-EBIT falls into.

Sino Biopharmaceutical EV-to-EBIT Calculation

Sino Biopharmaceutical's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	6100.996	/	759.999
	=	8.03

Sino Biopharmaceutical's current Enterprise Value is €6,101 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €760 Mil.

Sino Biopharmaceutical (FRA:SMZ1) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sino Biopharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	759.999	/	8311.281
	=	9.14 %

Sino Biopharmaceutical's Enterprise Value for the quarter that ended in Dec. 2023 was €8,311 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €760 Mil.

Sino Biopharmaceutical EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (FRA:SMZ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (FRA:SMZ1) Headlines

No Headlines